+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hypertrophy Drugs Market - Global Forecast 2026-2032- Product Image
Benign Prostatic Hypertrophy Drugs Market - Global Forecast 2026-2032- Product Image
New

Benign Prostatic Hypertrophy Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5977967
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The benign prostatic hypertrophy drugs market is evolving through clinical needs, regulatory changes, and commercial innovation, reshaping both therapeutic and strategic landscapes for industry leaders worldwide.

Market Snapshot: Benign Prostatic Hypertrophy Drugs Market

The benign prostatic hypertrophy drugs market grew from USD 5.89 billion in 2025 to USD 6.29 billion in 2026. It is projected to maintain a CAGR of 7.20%, reaching USD 9.59 billion by 2032. This growth underscores a robust demand for optimized therapies, driven by shifting disease dynamics, diversified treatment preferences, and the expansion of digital distribution channels across global geographies.

Scope & Segmentation

  • Therapeutic Classes: Covers 5-alpha reductase inhibitors (dutasteride, finasteride), alpha blockers (alfuzosin, doxazosin, silodosin, tamsulosin, terazosin), combination therapies (dutasteride plus tamsulosin, finasteride plus tamsulosin), and phytotherapy (beta-sitosterol, pygeum, saw palmetto).
  • Branded and Generic Dynamics: Differentiates between originator brands (e.g., Avodart, Flomax, Jalyn, Proscar) and generics, evaluating their impact on prescriber decisions and procurement patterns.
  • Distribution Channels: Assesses the rising roles of hospital pharmacies, online pharmacies, and retail pharmacies in reaching patients and shaping margin structures.
  • Dosage Forms: Reviews capsules, oral solutions, and tablets, with focused analysis on extended-release and immediate-release formulations for adherence and patient tolerability.
  • Regional Perspectives: Explores varied market conditions across the Americas, Europe, Middle East & Africa, and Asia-Pacific, emphasizing demographic drivers, regulatory frameworks, and unique access models.
  • Technology and Delivery Systems: Reflects on digital distribution advances, real-world evidence use, and the maturing role of telehealth-supported care and online channels.

Key Takeaways for Strategic Decision-Making

  • Product development now emphasizes formulation convenience, patient safety, and improved quality-of-life outcomes, balancing long-term management with immediate relief.
  • Evolving competitive dynamics see originator brands leveraging targeted lifecycle tactics, while generics focus on volume and affordability through both traditional and digital pharmacy channels.
  • Digitalization of distribution—including online pharmacies—reshapes patient engagement and access, compelling organizations to revisit channel partnerships and optimize outreach strategies.
  • Patient and physician preferences are broadening to include phytotherapeutic and integrative approaches, generating new opportunities for specialist brands and adjunctive offerings.
  • Expanded real-world evidence collection and telehealth support tools are improving personalized care and strengthening value communication to payers and prescribers.

Tariff Impact on Supply Chain Resilience and Economics

United States tariff adjustments in 2025 have recalibrated supply chain strategies for BPH therapies. Companies have diversified sourcing, invested in long-term supplier partnerships, and explored nearshoring options to mitigate the risk of tariff-induced volatility. These measures support margin protection and supply continuity while reinforcing regulatory compliance and supply chain transparency. Tariffs have differently shaped cost structures across branded and generic segments, prompting revised pricing and inventory management, and driving adoption of advanced supply chain management technologies throughout the industry.

Methodology & Data Sources

This report integrates in-depth secondary literature review, extensive stakeholder interviews, and segmentation mapping to deliver actionable insights. Clinical and regulatory sources, product labels, and expert validation ensure accuracy and relevance. Interview findings were rigorously cross-validated to resolve discrepancies and uphold quality.

Why This Report Matters

  • Enables senior leadership to benchmark market positioning, refine commercial strategies, and identify actionable pathways for portfolio and channel optimization.
  • Offers granular segmentation for effective targeting—supporting evidence-driven decision making across brand, generic, and phytotherapeutic segments globally.
  • Informs resilient supply chain planning and tariff management, supporting long-term operational stability.

Conclusion

Executive success in the benign prostatic hypertrophy drugs market depends on integrating clinical insights, operational flexibility, and adaptive channel strategies. Informed decisions based on current trends position organizations for future resilience and measurable value creation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Benign Prostatic Hypertrophy Drugs Market, by Drug Class
8.1. 5-Alpha Reductase Inhibitors
8.1.1. Dutasteride
8.1.2. Finasteride
8.2. Alpha Blockers
8.2.1. Alfuzosin
8.2.2. Doxazosin
8.2.3. Silodosin
8.2.4. Tamsulosin
8.2.5. Terazosin
8.3. Combination Therapy
8.3.1. Dutasteride + Tamsulosin
8.3.2. Finasteride + Tamsulosin
8.4. Phytotherapy
8.4.1. Beta-Sitosterol
8.4.2. Pygeum
8.4.3. Saw Palmetto
9. Benign Prostatic Hypertrophy Drugs Market, by Generic Status
9.1. Branded
9.1.1. Avodart
9.1.2. Flomax
9.1.3. Jalyn
9.1.4. Proscar
9.2. Generic
10. Benign Prostatic Hypertrophy Drugs Market, by Dosage Form
10.1. Capsule
10.1.1. Extended Release
10.1.2. Immediate Release
10.2. Oral Solution
10.3. Tablet
10.3.1. Extended Release
10.3.2. Immediate Release
11. Benign Prostatic Hypertrophy Drugs Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Benign Prostatic Hypertrophy Drugs Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Benign Prostatic Hypertrophy Drugs Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Benign Prostatic Hypertrophy Drugs Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Benign Prostatic Hypertrophy Drugs Market
16. China Benign Prostatic Hypertrophy Drugs Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc
17.6. Astellas Pharma Inc
17.7. Bayer AG
17.8. Boehringer Ingelheim International GmbH
17.9. Bristol-Myers Squibb Company
17.10. Eli Lilly and Company
17.11. Endo Pharmaceuticals Inc
17.12. GlaxoSmithKline plc
17.13. Ipsen S.A
17.14. Johnson & Johnson
17.15. Kaken Pharmaceutical Co Ltd
17.16. Kissei Pharmaceutical Co Ltd
17.17. Merck & Co Inc
17.18. Novartis AG
17.19. Pfizer Inc
17.20. Sanofi S.A
17.21. Sun Pharmaceutical Industries Ltd
17.22. Teva Pharmaceutical Industries Ltd
17.23. Viatris Inc
List of Figures
FIGURE 1. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 160. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 161. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 162. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 163. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 164. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 165. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 166. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 167. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 168. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 169. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 184. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 185. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 186. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 187. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 188. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 189. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 190. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 191. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 192. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 193. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 207. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 209. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 210. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 211. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 212. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 213. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 214. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 215. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 216. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 217. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 218. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 221. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 222. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 223. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 224. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 225. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 226. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 227. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 228. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 229. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 230. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 245. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 246. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 247. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 248. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 249. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 250. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 251. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 252. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 253. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 254. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 255. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 257. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 258. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 259. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 260. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 261. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 262. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 263. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 264. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 265. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 266. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 267. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 268. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 269. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 270. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 271. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 272. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 273. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 274. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 275. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 276. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 277. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 278. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 279. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 285. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018

Companies Mentioned

The key companies profiled in this Benign Prostatic Hypertrophy Drugs market report include:
  • AbbVie Inc
  • Astellas Pharma Inc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc
  • GlaxoSmithKline plc
  • Ipsen S.A
  • Johnson & Johnson
  • Kaken Pharmaceutical Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Sanofi S.A
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc

Table Information

Report AttributeDetails
No. of Pages181
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.29 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.59 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Benign Prostatic Hypertrophy Medication Market - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hypertrophy Medication Market - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Drugs for Benign Prostatic hypertrophy Market Report 2025 - Product Image

Drugs for Benign Prostatic hypertrophy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Benign Prostatic Hyperplasia Therapeutics Market - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hyperplasia Therapeutics Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report - Product Image

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2025-2033 - Product Image

Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2025-2033

  • Report
  • 137 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.